

HOW LOW CAN YOU GO?

Targeting of Deep Remission in the Management of Crohn's Disease



Sunday, October 27, 2024

6:00–7:30 AM ET

Pennsylvania Convention Center
Room 113AB



HOW LOW CAN YOU GO?

Targeting of Deep Remission in the Management of Crohn's Disease



Activity Description

Crohn's disease (CD) can cause progressive bowel damage, impaired quality of life, and permanent disability. Severity and presentation can vary widely from person to person, necessitating an individualized treatment approach. The use of more readily available imaging modalities such as intestinal ultrasound and magnetic resonance enterography can be added to standard monitoring practices to improve disease management. Additionally, targeting deeper remission at a histological level is an emerging treatment target for patients with CD. Clinicians in collaboration with a multidisciplinary care team must become knowledgeable on individualized care and novel imaging modalities to optimize treatment for patients with CD.

In this CME Outfitters live symposium, expert faculty will guide learners on how to integrate knowledge of the heterogeneity of CD in severity and manifestation into patient assessment and treatment. Learners will be instructed on utilizing alternative diagnostic and evaluation tools beyond colonoscopy for evaluating symptoms in patients with CD. Faculty will model incorporation of histopathologic treatment targets as an objective measure of inflammation in CD to inform clinical decision-making.

Target Audience

U.S. and international gastroenterologists, and gastroenterology nurse practitioners (NPs) and physician associates (PAs)

Financial Support

This activity is supported by an educational grant from Lilly.

This event is neither sponsored by nor endorsed by ACG.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

- Integrate knowledge of the heterogeneity of CD in severity and manifestation into patient assessment and treatment
- Utilize alternative diagnostic and evaluation tools beyond colonoscopy for evaluating symptoms in patients with CD
- Incorporate histopathologic treatment targets as an objective measure of inflammation in CD to inform clinical decision-making

Faculty

Bruce E. Sands MD, MS

Dr. Burrill B. Crohn
Professor of Medicine
Chief, Division of
Gastroenterology
Icahn School of Medicine
at Mount Sinai
Mount Sinai Health System
New York, NY

Millie D. Long MD, MPH

Professor of Medicine
Vice-Chief for Education
Director, Gastroenterology
and Hepatology Fellowship
Program
Division of Gastroenterology
and Hepatology
University of North Carolina
Chapel Hill, NC

Marita Kametas MSN, APN, FNP-BC, CMSRN, COCN

Inflammatory Bowel Disease
Advanced Practice Nurse
Manager of Gastroenterology
Advanced Practice Provider
Services
The University of Chicago
Medicine
Chicago, IL

HOW LOW CAN YOU GO?

Targeting of Deep Remission in the Management of Crohn's Disease



Accreditation



JOINTLY ACCREDITED PROVIDER
INTERPROFESSIONAL CONTINUING EDUCATION

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



IPCE CREDIT™

IPCE

This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education Credit for learning and change.

Physicians (ACCME)

CME Outfitters, LLC, designates this live activity for a maximum of 1.5 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC)

This activity is designated for 1.5 contact hours. **Pharmacotherapy:** ANCC definition of pharmacotherapeutic content is that it may include but is not limited to drug specific information, safe prescribing practices, safe medication administration, prescribing methodologies, new regulations, or similar content. **California Residents:** This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC's provider number is CEP15510.



PAs (AAPA)

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.



RCP Canada

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.



MIPS

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Certificate of Participation

This activity was certified for a maximum of 1.5 *AMA PRA Category 1 Credit(s)*™.

This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education Credit for learning and change.



ABIM MOC

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

HOW LOW CAN YOU GO?

Targeting of Deep Remission in the Management of Crohn's Disease



Faculty



Bruce E. Sands, MD, MS

*Dr. Burrill B. Crohn Professor of Medicine
Chief, Division of Gastroenterology
Icahn School of Medicine at Mount Sinai
Mount Sinai Health System
New York, NY*

Bruce E. Sands, MD, MS, is the Dr. Burrill B. Crohn Professor of Medicine in the Icahn School of Medicine at Mount Sinai in New York City and Chief of the Division of Gastroenterology in the Mount Sinai Health System. He is an expert in the management of inflammatory bowel disease (IBD) and has earned an international reputation for his care of patients with complex and refractory disease.

Dr. Sands was awarded his BA and MD from Boston University in Massachusetts, and he trained in internal medicine at the Hospital of the University of Pennsylvania in Philadelphia. After completing a gastrointestinal fellowship at Massachusetts General Hospital (MGH) in Boston, he joined the faculty of Harvard Medical School in Cambridge and served as the Acting Chief of the Gastrointestinal Unit at MGH. He moved to Mount Sinai in 2010 as Chief of the Dr. Henry D. Janowitz Division of Gastroenterology.

Dr. Sands is a past Chair of the Clinical Research Alliance of the Crohn's & Colitis Foundation of America, and served as Chair of the Immunology, Microbiology, and Inflammatory Bowel Disease Section of the American Gastroenterological Association. Additionally, Dr. Sands was the Chair of the International Organization for the Study of IBD (IOIBD). In 2016, Dr. Sands was awarded the Dr. Henry Janowitz Lifetime Achievement Award from the Crohn's & Colitis Foundation, that organization's highest honor. In 2023, Dr. Sands was the recipient of the Jacobi Medallion, Mount Sinai's most prestigious award for distinguished contributions to the field of medicine or extraordinary service to the hospital, health system, School of Medicine, or alumni community.

Dr. Sands is widely recognized for his innovative treatment of Crohn's disease and ulcerative colitis and for his expertise in the clinical investigation of new therapeutics. His research also explores IBD epidemiology and includes the creation of a population-based IBD cohort in Rhode Island, a project funded by both the National Institute of Health and the Centers for Disease Control and Prevention. He has served as an associate editor for the journal *Gastroenterology*, and has published more than 300 original manuscripts in leading journals such as *Gut*, *Gastroenterology*, and the *American Journal of Gastroenterology*. He was the lead investigator of the landmark studies ACCENT 2, UNIFI, and VARSITY, all published in the *New England Journal of Medicine*, and SEAVUE, published in *The Lancet*.

DISCLOSURES

Dr. Sands reports the following financial relationships:

Consultant: Abbvie Inc.; Amgen Inc.; AstraZeneca; Boehringer-Ingelheim; Bristol Myers Squibb Company; Celltrion Inc.; Lilly; Galapagos; Genentech, Inc.; Gilead Sciences, Inc.; GSK; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Pfizer Inc.; Takeda Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; and Ventyx Biosciences, Inc.

Research Support: Bristol Myers Squibb and Janssen Pharmaceuticals, Inc.

Stock Shareholder (directly purchased): Ventyx Biosciences, Inc.

Other financial or material support: Editorial support from AbbVie Inc., Bristol Myers Squibb Company, Celltrion Inc., Lilly, Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Pfizer Inc., and Takeda Pharmaceuticals U.S.A., Inc.

HOW LOW CAN YOU GO?

Targeting of Deep Remission in the Management of Crohn's Disease



Faculty



Millie D. Long, MD, MPH

Professor of Medicine

Vice-Chief for Education

Director, Gastroenterology and Hepatology Fellowship Program

Division of Gastroenterology and Hepatology

University of North Carolina

Chapel Hill, NC

Millie D. Long, MD, MPH, is board certified in internal medicine, preventive medicine, and gastroenterology. Dr. Long received her medical degree from University of Virginia in 2002. She then completed residency in internal medicine and a chief residency at University of Alabama at Birmingham. She completed fellowships in gastroenterology and hepatology, preventive medicine, and inflammatory bowel disease, all at University of North Carolina. She is currently Professor of Medicine in the Department of Medicine and Director of the Gastroenterology and Hepatology Fellowship Program at University of North Carolina at Chapel Hill.

Dr. Long's clinical practice is at the UNC Multidisciplinary Inflammatory Bowel Diseases (IBD) Center. Her research interests include prevention of complications of IBD, women's health, and clinical epidemiology. Dr. Long has contributed to over 200 peer-reviewed publications, book chapters, and review articles and to the medical literature. She is the current co-Editor in Chief of the *American Journal of Gastroenterology*. She also serves as an invited reviewer for journals such as *Inflammatory Bowel Diseases* and *Gastroenterology*.

Dr. Long is a fellow of the American College of Gastroenterology, where she serves on the Board of Trustees. She is also a fellow of the American Gastroenterological Association and the Crohn's and Colitis Foundation, where she co-chairs the Clinical Research Alliance.

DISCLOSURES

Dr. Long reports the following financial relationships:

Consultant: AbbVie Inc.; Bristol Myers Squibb Company; Intercept Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Pfizer Inc.; Prometheus Biosciences, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Target RWE

Research Support: Lilly; Pfizer Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

HOW LOW CAN YOU GO?

Targeting of Deep Remission in the Management of Crohn's Disease



Faculty



Marita Kametas, MSN, APN, FNP-BC, CMSRN, COCN

Inflammatory Bowel Disease Advanced Practice Nurse

Manager of Gastroenterology Advanced Practice Provider Services

The University of Chicago Medicine

Chicago, IL

Marita Kametas, MSN, APN, FNP-BC, CMSRN, COCN, is a family nurse practitioner and ostomy specialist who treats adult patients with inflammatory bowel disease (IBD). She serves as the manager for the Advanced Practice Gastroenterology Service at the University of Chicago in Illinois. She volunteers her time as a mentor for the Crohn's and Colitis Advanced Practice Provider (APP) mentorship program and delivers empowering lectures to APPs to optimize their care of patients with IBD. She was awarded the honor of Distinguished APP of 2023 at the University of Chicago. She is currently pursuing a doctorate in nursing practice and a master's degree in public health at Johns Hopkins University in Baltimore, Maryland with an emphasis on diversity, equity, and inclusion.

DISCLOSURES

Ms. Kametas reports the following financial relationships:

Advisory Board: Lilly and Pfizer Inc.

Consultant: TKG Therapeutics, Inc.

Grants: GI Research Foundation

Speakers Bureau: AbbVie Inc.;
Janssen. Pharmaceuticals, Inc.;
and Pfizer Inc.

HOW LOW CAN YOU GO?

Targeting of Deep Remission in the Management of Crohn's Disease



Disclosure Declarations

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Peer Reviewers

Rebecca Vargas-Jackson, MD—no disclosures to report.

Shirley Michelle Franks, MSN, APRN, FNP-BC—no disclosures to report.

CMEO Staff/Planners

Keshia Pitt, PhD—no disclosures to report.

John Jones, PharmD—no disclosures to report.

Kasey Brandt, PharmD—no disclosures to report.

Scott J. Hershman, MD, FACEHP, CHCP—no disclosures to report.

Sandra Caballero, PharmD—no disclosures to report.

Sharon Tordoff—no disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac.

HOW LOW CAN YOU GO?

Targeting of Deep Remission in the Management of Crohn's Disease



Instructions for Interactive Technology

Use one of the iPads provided at your table to answer polling questions, view onsite presentations, and submit questions to the faculty. Please see additional information below.

ASK FACULTY A QUESTION

Select the Ask Question tab below the slide viewer to submit a question. If your question is for a specific faculty member, please include their name. Your question will be shared with the faculty for the question-and-answer portion of the session.

VIEW AND TAKE NOTES ON PRESENTATION SLIDES

Select the Take Notes tab to take notes during the meeting. All of the notes you take during the meeting will be emailed to the address provided within 5 business days.

Obtaining Credit

To receive CME/CE credit for this activity, scan the QR code to create an account.



Downloadable Resources

Downloadable resources will be available at cmeoutfitters.com/howlowresources.

Engage with Us

Follow us [@cmeoutfitters](https://twitter.com/cmeoutfitters) for announcements about upcoming CME opportunities, health care news, and more!

Thank you for joining us today!

